Kidney injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Preclinical Biomarker Qualification Studies
A Panel of Urinary Biomarkers to Monitor Reversibility of Renal Injury and a Serum Marker with Improved Potential to Assess Renal Function
October 5, 2010 Renal Biomarker Qualification Submission: A Dialog Between the FDA-EMEA and Predictive Safety Testing Consortium
October 5, 2010 Urinary Clusterin, Cystatin C, [beta]2-Microglobulin and Total Protein as Markers to Detect Drug-Induced Kidney Injury
Critical Path Institute President/CEO Receives Award of Excellence Raymond L. Woosley, MD, PhD, President/CEO of Tucson-based Critical Path Institute (CPI), was recently presented with the prestigi